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Abstract
Background: In addition to their original applications to lowering cholesterol, statins display multiple neuroprotective
effects. N-methyl-D-aspartate (NMDA) receptors interact closely with the dopaminergic system and are strongly implicated
in therapeutic paradigms of Parkinson’s disease (PD). This study aims to investigate how simvastatin impacts on
experimental parkinsonian models via regulating NMDA receptors.
Methodology/Principal Findings: Regional changes in NMDA receptors in the rat brain and anxiolytic-like activity were
examined after unilateral medial forebrain bundle lesion by 6-hydroxydopamine via a 3-week administration of simvastatin.
NMDA receptor alterations in the post-mortem rat brain were detected by [
3H]MK-801(Dizocilpine) binding
autoradiography. 6-hydroxydopamine treated PC12 was applied to investigate the neuroprotection of simvastatin, the
association with NMDA receptors, and the anti-inflammation. 6-hydroxydopamine induced anxiety and the downregulation
of NMDA receptors in the hippocampus, CA1(Cornu Ammonis 1 Area), amygdala and caudate putamen was observed in 6-
OHDA(6-hydroxydopamine) lesioned rats whereas simvastatin significantly ameliorated the anxiety-like activity and restored
the expression of NMDA receptors in examined brain regions. Significant positive correlations were identified between
anxiolytic-like activity and the restoration of expression of NMDA receptors in the hippocampus, amygdala and CA1
following simvastatin administration. Simvastatin exerted neuroprotection in 6-hydroxydopamine-lesioned rat brain and 6-
hydroxydopamine treated PC12, partially by regulating NMDA receptors, MMP9 (matrix metalloproteinase-9), and TNF-a
(tumour necrosis factor-alpha).
Conclusions/Significance: Our results provide strong evidence that NMDA receptor modulation after simvastatin treatment
could partially explain its anxiolytic-like activity and anti-inflammatory mechanisms in experimental parkinsonian models.
These findings contribute to a better understanding of the critical roles of simvastatin in treating PD via NMDA receptors.
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Introduction
As hydroxymethylglutaryl-coenzyme reductase inhibitors, sta-
tins have been widely used to reduce serum low-density lipoprotein
(LDL) cholesterol. It has been well established that statins reduce
the risk of ischaemic heart disease events and cerebrovascular
stroke, and have potential applications in multiple sclerosis,
traumatic brain injury, and Alzheimer’s disease (AD). Recently,
increasing animal and clinical evidence has shown that statins have
obvious effects on cognition, dementia and progressive Parkinson’s
disease (PD), even though conflicting results were observed and the
exact mechanisms remain unclear [1]. Anti-inflammatory inter-
ventions induced by statins were also observed in various
neurological disease models [2]. The application of statins’ may
have potentially beneficial effects on neuropsychological disorders
such as PD.
N-methyl-D-aspartate (NMDA) receptors, one of the families of
ionotropic glutamate receptors, are widely studied and abundant
in the cerebral cortex, hippocampus, nucleus accumbens and
striatum [3,4,5]. Changes of NMDA receptor populations in the
brain are closely associated with many important brain functions,
including neuronal apoptosis [6], attention and movement [7] as
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20945well as anxiety and depression [8]. Recent studies have
demonstrated that NMDA receptors in different brain regions
such as the amygdala and hippocampus mediate anxiety and fear-
related activity [9,10]. Mishizen reported that markedly reduced
NMDA receptor binding levels were observed in the hippocampus
and striatum of aged mice and AD patients [11] in association with
the cognitive decline and anxiety. One clinical study by Tsang
demonstrated that the NMDA receptor NR2A(N-methyl,D-
aspartate receptor subunit 2A subunit)was significantly reduced
in the orbitofrontal gyrus of high-anxiety Alzheimer’s patients in
comparison to low anxiety patients, indicating that changes in the
expression of NMDA receptors in the brain may modulate an
anxiety-like activity [12]. In addition, overactivation of NMDA
receptors is associated with neuronal excitotoxicity leading to cell
death [13]. These findings strongly suggest the alterations of brain
NMDA receptors may play important roles in neuropsychiatric
and movement related disorders.
PD is the second most common neurodegenerative disorder
following AD and is characterized by disturbance of the central
dopaminergic system and imbalances in some non-dopaminergic
systems, including the glutamatergic system. It has been well
documented that there is a close interaction between brain
glutamatergic NMDA receptors and monoamine dopaminergic
systems [14]. Dopaminergic disturbances in the brain may lead to
glutamatergic NMDA receptor changes [15] and vice versa [16].
Fiorentini indicated that in the 6-hydroxydopamine-lesioned rat
model of PD, D1/NMDA receptor expression was profoundly
decreased in the lesioned striatum [17]. Several lines of studies
showed that in rodent and primate models of PD NMDA receptor
antagonists increased dopaminergic neuronal survival and normal-
ized the levodopa-induced abnormal motor response [18,19]. Our
previous studies and one by Selley [20,21] have reported that
simvastatin profoundly affects D1/D2 dopamine receptors and
altered dopamine content in various brain regions, and our recent
work has also indicated that simvastatin up-regulates the NMDA
receptors in different regions of the rat brain [22]. Increasing
evidence shows that inflammatory responses, which are character-
ized by activation of microglia [23,24] and accumulation of
inflammatory mediators such as inflammatory cytokines and
proteases in the substantia nigra and striatum [25,26], are thought
to be responsible for the progression of PD. Hernandez-Romero
demonstrated that in LPS-induced PD rats, simvastatin delayed
LPS-mediated dopaminergic degeneration via activating the
neurotrophic factor BDNF and inhibiting the induction of
interleukin-1beta, tumour necrosis factor-alpha, iNOS, mitogen-
activated protein kinases, cAMP response element-binding protein,
and Akt [27]. Ghosh also found that statins attenuated the
activation of both p21(ras) and NF-kappaB in MPP(+)-mediated
microglial cellsandMPTP-intoxicatedmice,accompanyingslowing
down the progression of dopaminergic neuronal loss and improving
motor function [28]. In this study, we sought to determine whether
the application of simvastatin influences the expression of NMDA
receptors in the PD models and to identify any effects associated
with anti-inflammation and anti-excitotoxicity.
To address this issue, we used [
3H] MK-801 binding
autoradiography to determine the response of NMDA receptors
to chronic simvastatin treatment across a wide range of brain
structures in Parkinsonian rats. Behavioural study was also used to
explore the association between the alterations of NMDA
receptors and anxiety. In addition, in vitro study was used to
investigate the neuroprotection of simvastatin in PC12 cells
(Pheochromocytoma 12 Cells)following 6-hydroxydopamine (6-
OHDA) neurotoxicity and its association with NMDA receptor
and anti-inflammatory responses. This work finds a possible
correlation between simvastatin and NMDA receptors based on in
vivo and in vitro parkinsonian models.
Materials and Methods
Ethics Statement
The animal study has been approved by the University of
Wollongong Animal Ethics Committee (project number: AE 08/
03) and all animal experiments were conducted in compliance
with the National Institute of Health Guide for the Care and Use of
Laboratory Animals (NIH Publications No. 80-23) revised 1996
guidelines and National Health and Medical Research Council
(NHMRC) Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes (2004).
6-OHDA-Lesioned Parkinsonian Rats and Drug
Treatments
Twenty-two male Sprague-Dawley rats (230–250 g) were
obtained from the Animal Resources Centre (Perth, Western
Australia, Australia) and housed individually in environmentally
controlled conditions with ad libitum access to standard laboratory
chow and water. They were randomized with sixteen rats to create
a 6-OHDA-induced parkinsonian treated group, among which
eight rats were orally treated with simvastatin (10 mg/kg/day)
[21,22] and eight rats received saline orally. The 6-OHDA
lesioned Parkinsonian rat model was performed as described in
our previous works [29]. Briefly, male Sprague–Dawley rats
(weight 230–250 g) were anesthetized with 75 mg/kg ketamine
and 10 mg/kg xylazine (Troy Laboratories Pty, Ltd., Australia).
Lesions were performed by unilaterally injecting 6-OHDA into the
medial forebrain bundle. The control group received vehicle. One
6-OHDA lesioned rat that received simvastatin orally died after
the surgery. After three weeks of 6-OHDA-induced Parkinsonian
treatment, rats from each group were sacrificed to examine the
NMDA receptor binding.
Elevated Plus Maze (EPM)
Three weeks after 6-OHDA lesion, rats were tested in the EPM,
where the level of anxiety was assessed. The procedure for this test
was as described in previous studies [22,30]. The EPM consists of
two open arms (506761 cm) and two closed arms (5067630 cm)
with an open roof, arranged around a central platform (767 cm) so
that the arms oppose each other. Light intensity was set at
approximately 100 lux along the open arms. A single rat was placed
on the central platform facing an open arm and observed for
5 minutes. The number of open and closed arm entries, duration in
the open and closed arms and center were scored using a computer
program. From these measures, the percentage of time spent in the
open arms (1006time open/time open+time closed) and the
percentage of open-arm entries (1006time open-arm entries/total
entries) were calculated for each animal as the anxiety indexes.
Increased time, and/or entries traveled in the open arms of the
EPMareinterpretedasreduced anxiety-like behavior.The criterion
for recording an entry was that the animal had at least half of its
bodylength entered into the arm/center. A ratwasconsidered to be
in the central platform zone if its body was positioned in a closed
arm and the head and front paw/s were on the central platform.
Tyrosine Hydroxylase Immunohistochemistry Staining
and Cell Counting in Substantia Nigra Pars Compacta
(SNpc)
After the EPM behavioural test, control and 6-OHDA lesioned
rats with or without simvastatin administration were used for
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described in Yuan’s study [31]. Briefly, endogenous peroxidase
was quenched with 0.3% H2O2 (30 min). Non-specific binding
was blocked with 1.5% normal goat serum (Vectastain rabbit IgG
ABC kit) (60 min). This was followed by application of TH
primary antibody (rabbit polyclonal anti-tyrosine hydroxylase,
Millipore Corporation, AB152) at 1:500 in blocking solution. The
sections were incubated with the biotinylated anti-rabbit second-
ary antibody at 1:200 (Vectastain rabbit IgG ABC kit) for 60 min.
The horseradish peroxidase conjugate ABC (Vectastain rabbit IgG
ABC kit) was applied for 60 min, followed by the nickel stock
(DAB, Vector SK-4100). Intact dopaminergic cells that were
round with clear nuclei or cytoplasm were counted; this analysis
was carried out on five sections per animal through the SNpc
anterior-posterior axis. The number of TH-positive cells was
counted in 30 randomly selected fields. Data are means 6 SE of
values from three independent experiments.
[
3H] MK-801 Binding Autoradiography
After the EPM behavioural test, rats were sacrificed with an
overdose of CO2 (carbon dioxide) between 0700 and 0900 hours
in order to minimize the impact of circadian variation on binding
density and the brains were immediately removed and frozen in
liquid nitrogen. Coronal brain sections (14 um) were cut at 217uC
with a cryotome (Clinicut cryostat; Bright Instruments) and thaw-
mounted onto poly-L-lysine-coated microscope slides (Polysine
TM,
Menzel GmbH & Co KG). Consecutive sections were used for the
detection of the NMDA receptor binding site. Identification of
neuroanatomical structures was performed according to a
standard rat brain atlas [32]. [
3H] MK-801 autoradiography
was performed as described in our previous works [22]. Briefly,
sections were preincubated for 2.5 h at room temperature in
30 mM N-2-hydroxyethyl piperazine-NO-2-ethanesulphonic acid
(HEPES) buffer (pH 7.5), containing 100 mM glycine, 100 mM
glutamate, 1 mM ethylenediaminetetraacetic acid (EDTA) and
20 nM [
3H]MK-801. Non-specific binding was determined by
incubating adjacent sections with [
3H] MK-801 in the presence of
20 mM MK-801. Following incubation, sections were washed
three times for 20 min each at 1uC in 30 mM HEPES containing
1 mM EDTA (pH 7.5).
Quantification of [
3H] MK-801 Binding
Quantification of binding sites was performed on a high-
resolution Beta Imager (BioSpace, Paris, France) according to our
previous study [22]. Briefly, sections were placed inside the
detection chamber of the Beta Imager and scanned for 3.5 h at a
high-resolution setting. The levels of bound radioactivity in the
brain sections were directly determined by counting the number of
b-particles emerging from the tissue sections, which was followed
by analysis of the activity in the regions of interest using the Beta
Vision Plus program (BioSpace). The radioligand binding signal
was expressed in counts per minute per square millimetre (cpm/
mm
2), and a series of sections with known amounts of ligands were
used as standards in all scans, which allowed the measurement of
radioligand binding signals to be converted to nCi (nanocurie)/mg
tissue equivalents. The [
3H] MK-801 binding density in various
brain regions was quantified by measuring the average density of
each region in three to five adjacent brain sections.
Cell Culture and Treatments
PC12 cell culture was performed as described in Rodriguez-
Blanco’s study [33]. Briefly, PC12 cells were routinely maintained
in DMEM(Dulbecco’s Modified Eagle Medium)supplemented
with 5% fetal bovine serum, 10% horse serum, benzyl penicillin
100 U/ml, and streptomycin 100 mg/ml (Gibco). For all
experiments, cells were seeded on the 96-well plates or 6-well
plates at a density of 1.0610
5 cells/ml for 24 h. Three groups were
treated with DMEM, 6-OHDA (100 uM), and 6-OHDA
(100 uM)+simvastatin (0.6 ug/ml), respectively. For the determi-
nation of cell viability, 3-(4,5-dimethyl-2-thiazo-lyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) assay, glutamate concentration,
and lactate dehydrogenase (LDH) release assay were conducted.
MTT assay and Apoptotic Cells
The MTT assay was carried out with modifications according
to Rodriguez’s study [33] to measure the PC12 viability after 6-
OHDA or 6-OHDA+simvastatin treatment. The results were
expressed as a percentage of the control group. To measure
apoptosis in this study, cells were stained with Hoechst 33342.
Briefly, PC12 cells were seeded at a density of 1610
5 cells/well
into 24-well plates. After incubation with 6-OHDA (100 uM) or 6-
OHDA (100 uM)+simvastatin (0.6 ug/ml) for 24 h, cells were
treated with Hoechst 33342 (10 mg/ml) (Sigma) for 20 min at
37uC in the dark. The cells were examined using an Olympus
IX70 inverted fluorescence microscope. Ten randomly selected
fields were acquired from each treatment and at least 500 cells
were counted. PC12 apoptosis was also evaluated by flow
cytometry using Annexin V-FITC (fluorescein isothiocyanate)
(Bender MedSystems, Burlingame, CA): apoptotic cells display
phosphatidylserine on the outside of the plasma membrane.
Changes in phosphatidylserine asymmetry were analyzed by
measuring Annexin V binding to the cell membrane.
LDH Assay and Glutamate Measurement
Cell viability was also measured by determining the activity of
LDH released into the medium [33]. After the 6-OHDA or 6-
OHDA+simvastatin treatments, released LDH was measured, and
cells were lysed to obtain total LDH. Measurement of total and
released LDH activity was undertaken following specifications of
the In vitro Toxicology Assay Kit LDH-based Tox-7 (Sigma-
Aldrich, USA), and released LDH was normalized to total LDH.
Data were represented as a percentage of LDH in the 6-OHDA
group, which was designated as 100%. The concentration of
glutamate was measured according to the Glutamate Assay
Protocol (BioVision, USA).
Protein Extraction, Subcellular Fractionation, and
Western Blotting Analysis
After 6-OHDA or 6-OHDA+simvastatin treatment, cells were
harvested by using cell scrapers and washing in ice-cold PBS, and
lysed with two different ice-cold lysis buffers [33]. The superna-
tants were collected for protein determination by BCA (bicinch-
oninic acid) assay (Pierce, Inc., Rockford, IL, USA), and protein
was run in NuPage Bis-Tris 10% gels (Invitrogen) and transferred
to PVDF(polyvinylidene fluoride)membranes (Amersham Biosci-
ence, Ltd., Buckinghamshire, UK). The membranes were blocked
in 5% skim milk, 0.05% Tween 20, and Tris-buffered saline (TBS)
for 1 h. PVDF membranes were incubated in primary antibodies:
rabbit anti-TNF-a (1:400), rabbit anti-matrix metalloproteinase-9
(MMP9) (1:500), rabbit anti-NMDAR1(1:800), or rabbit anti-b-
actin (1:1000) (all from Abcam, Cambridge, MA, USA), for
overnight at 4uC. The next day, horseradish peroxidase-conjugat-
ed secondary antibodies (Calbiochem, San Diego, CA, USA) were
applied. Peroxidase-conjugated streptavidin and substrate were
used for detection. Negative controls were performed by omitting
the primary antibodies. The images were analyzed using the NIH
Image J software.
Simvastatin Regulates NMDA Receptors in PD Models
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Immunocytochemistry was performed and modified according
to Iida’s study [34]. After the nonspecific reaction was blocked
with PBS containing 10% (wt/vol) bovine serum albumin (BSA),
cells were incubated with the primary antibodies (anti-NMDAR1,
1: 200; anti-TNF-a, 1:100; Abcam, Cambridge, MA, USA) in PBS
containing 3% (wt/vol) BSA overnight. The next day, the
secondary antibody (1:200,Invitrogen, Carlsbad, CA, USA) was
applied for 1 h. After the samples were washed three times with
PBS, they were embedded in 200 ul Hoechst 33342 (concentration
10 ug/ml) for 5 minutes. The images were obtained using a Leica
DMI 4000B microscope (Leica Corp.). Image analysis software
Pro Plus 6.0 (Media Cybernetics Inc, Bethesda, USA) was applied
to measure the intensity of NR1 and TNF-a receptors.
Statistical Analysis
Data were expressed as mean 6 SEM. Data related to
[
3H]MK-801 binding densities for each brain region, TH
immunohistochemistry staining in the SNpc, MTT, LDH,
Hoechst 33342, flow cytometry analysis, and protein quantifica-
tion with western blot were analyzed using a one-way ANOVA
(analysis of variance) followed by Tukey’s post hoc analysis
(Statistical Product and Service Solutions 15.0 program, Chicago,
IL). Student’s t-test was employed to determine the statistical
significance of EPM test and immunocytochemistry staining. p
values of less than 0.05 were regarded as statistically significant.
Results
Effects of 6-OHDA Lesion and Simvastatin on TH
Immunohistochemistry Staining in the SNpc
In Fig. 1 low-power photomicrograph Fig. 1A (scale bar,
450 mm) shows a coronal section of the unlesioned side through
the midbrain, and Fig. 1B shows a lesioned section through the
midbrain. Photomicrographs from Fig. 1D and Fig. 1E are taken
from Fig. 1A and Fig. 1B at higher magnification, showing the
unlesioned (Fig. 1D, left) and lesioned (Fig. 1E, right) side SNpc,
respectively. After 6-OHDA MFB(medial forebrain bundle)lesion,
cells in the SNpc displayed shrinkage. The typical TH immuno-
reactivity (Fig. 1D, scale bar, 120 mm) within the SNpc is located
relative to the intact side; severe cell loss within the SNpc is
ispilateral to the 6-OHDA MFB lesion (Fig. 1E). The injection of
6-OHDA produced a significant 78% decrease in the number of
TH immuno-reactive dopaminergic neurons on the lesioned side
of SNpc as compared to the control (F[2,18]=142.77, p,0.001;
Fig. 1G), whereas simvastatin treatment prevented this neuronal
loss (Fig. 1C and Fig. 1F), keeping the number of TH
immunoreactive neurons near control values (F[2,18]=142.77,
p,0.001; Fig. 1G).
Effects of 6-OHDA Lesion and Simvastatin Treatment on
[
3H]MK-801 Binding
Specific [
3H]MK-801 binding was observed in most brain
regions examined, and nonspecific binding was observed to be less
than 5% (Fig. 2A). One way ANOVA revealed significant changes
in [
3H]MK-801 binding in the hippocampus (F[2,18]=8.665),
CA1 (F[2,18]=7.486), amygdala (F[2,18]=17.316) and caudate
putamen (F[2,18]=5.001) among 6-OHDA-lesioned rats. Specif-
ically, Tukey’s post-hoc analysis showed that three weeks after 6-
OHDA lesion [
3H]MK-801 binding was significantly decreased in
the hippocampus (23%, p,0.001), CA1 region (26%, p,0.001),
amygdala (18%, p,0.001) and caudate putamen (15%, p=0.001)
as compared to the controls (Fig. 2B). However, after three-week
administration with simvastatin, [
3H]MK-801 binding sites in
these examined regions had clearly been restored to baseline
levels. Specifically, simvastatin significantly increased [
3H]MK-
801 binding density in the hippocampus (31%, p,0.001), CA1
region (17%, p=0.007), amygdala (18%, p,0.001) and caudate
putamen (13%, p=0.01) in comparison to the 6-OHDA lesioned
PD rats (Fig. 2B). In addition, we did not detect [
3H]MK-801
binding in the substantia nigra among either groups because the
density was very low (not detectable), which is consistent with
Araki’s study [35].
Anxiety Activity and its correlation with [
3H]MK-801
binding
Fig. 3A presents the anxiety-like behavior effect in the EPM test
for control, 6-OHDA-lesion and 6-OHDA-lesion with simvastatin
treatment groups. Student’s t-test showed an obvious decrease
(66%, Student t-test: t=4.803, p,0.001) in the duration of open-
arm activity in comparison to controls (Fig. 3A). When compared
to 6-OHDA-lesion PD rats, simvastatin significantly restored the
reduction in the duration of open-arm activity (86%, Student t-
test: t=22.422, p=0.031). Student’s t-test also showed an obvious
decrease (49%, Student t-test: t=2.688, p=0.02, Fig. 3A) in the
entries into the open arms in comparison to controls. When
compared to 6-OHDA-lesion PD rats, simvastatin showed an
increased tendency but not significant effect in the entries into the
open arms (Student t-test: t=2.072, p=0.060, Fig. 3A). A
significant positive correlation was identified between the
[
3H]MK-801 binding density in the hippocampus and the
duration of time spent in the open arm (r=0.485 Pearson’s
correlation, p=0.026) in the EPM test (Fig. 3B). There were also
significant correlations between the [
3H] MK-801 binding density
in the amygdala (r=0.622, p=0.003) and CA1 (r=0.638,
p=0.002), respectively, with the duration of open-arm activity
(Fig. 3B). However, no significant correlation was observed
between [
3H]MK-801 binding density in the caudate putamen
and the duration of time spent in the open arm of EPM (r=0.380,
p=0.202) (Fig. 3B).
Effects of 6-OHDA and Simvastatin on PC12 Cell Viability
and Apoptosis
The MTT value in the 6-OHDA treated group was significantly
reduced compared with controls (F[2,26]=580.791, ***p,0.001,
6-OHDA vs controls, n=9; Fig. 4A), but simvastatin upregulated
this reduction (F[2,26]=580.791, {{{p,0.001, 6-OHDA vs 6-
OHDA+sim, n=9; Fig. 4A). We examined the cultures exposed to
6-OHDA for the presence of apoptotic nuclei in PC12 cells using
Hoechst 33342. Intact nuclei (blue Hoechst 33342 staining blue)
and condensed/fragmented nuclei (bright blue Hoechst 33342
staining) were considered alive and apoptotic cells (Fig. 4B, C, D),
respectively. The exposure of the PC12 cultures to 6-OHDA
(100 uM, 24 h) significantly increased the number of apoptotic
cells by 4.75 times compared with controls (F[2,26]=316.785,
***p,0.001, 6-OHDA vs controls, n=9; Fig. 4E); however,
simvastatin incubation profoundly reduced this elevation in the
number of apoptotic cells (F[2,26]=316.785, {{{p,0.001, 6-
OHDA vs 6-OHDA+sim, n=9; Fig. 4E). Apoptotic cells were
further verified by flow cytometry analysis after being labeled with
Annexin V. The result showed that 6-OHDA induced profound
apoptosis (F[2,14]=166.335, 4.5960.9% vs 14.9761.25%, con-
trols vs 6-OHDA, p,0.01, n=5; Fig. 4F,G) but simvastatin
incubation attenuated this apoptotic death (F[2,14]=166.335,
14.9761.25% vs 6.0960.64%, 6-OHDA vs 6-OHDA+sim,
p,0.01, n=5; Fig. 4G, H).
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LDH is released from the cells following membrane collapse, and
the released LDH is usually considered a sign of late cell death [33].
Our result showed that LDH in 6-OHDA incubated PC12
increased by 1.74 times compared with controls (F[2,26]=
158.486, ***p,0.001, 6-OHDA vs controls, n=9; Fig. 5A), but
simvastatin incubation abolished this elevation (F[2,26]=158.486,
{{{p,0.001,6-OHDAvs6-OHDA+sim,n=9;Fig.5A).Glutamate
is the most abundant excitatory neurotransmitter and is recognized
as an important sign of cell death. In 6-OHDA incubated PC12,
glutamate increased by 1.43 times compared with controls
(2.13860.03 mm vs 1.4960.01 mm, 6-OHDA vs controls,
F[2,26]=34.244, ***p,0.001, n=9; Fig. 5B), but simvastatin
incubation abolished this elevation (2.13860.03 mm vs
1.6460.01 mm, 6-OHDA vs 6-OHDA+sim, F[2,26]=34.244,
Figure 1. Effects of 6-OHDA lesion and simvastatin on TH immunohistochemistry staining in the SNpc. Figs. A, B, C shows TH staining in
low-power photomicrograph in the SNpc of unlesioned, 6-OHDA-lesioned, and 6-OHDA-lesioned with simvastatin treatment groups, respectively.
Bar=450 mm. Figs. D, E, F shows TH staining at higher magnification photomicrograph in the SNpc of unlesioned, 6-OHDA-lesioned, and 6-OHDA-
lesioned with simvastatin treated groups, respectively. Bar=120 mm. Fig. 1G represents the average number of TH-positive dopaminergic neurons in
the SNpc of unlesioned (control), 6-OHDA lesioned, and 6-OHDA lesioned with simvastatin treatment groups. The values represent mean 6SEM,
n=6–8. ***p,0.001, 6-OHDA group versus control group; {{{ p,0.001, 6-OHDA+simvastatin group versus 6-OHDA group.
doi:10.1371/journal.pone.0020945.g001
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protection against PD in this in vitro model.
Simvastatin Regulates the Levels of NMDANR1 Receptors,
TNF-a MMP9 in 6-OHDA-treated PC12 cells using Western
blot analysis
6-OHDA incubation pronouncedly increased levels of NR1
receptors as compared with controls (F[2,21]=142.568,
***p,0.001, 6-OHDA vs controls, n=6–9, Fig. 6), but this
elevation was significantly abolished following simvastatin treat-
ment (F[2,21]=142.568, {{{p,0.001, 6-OHDA vs 6-OHDA+sim,
n=6–9, Fig. 6). To explore whether the modulation of NR1
receptors following simvastatin treatment is correlated with anti-
inflammatory responses, the levels of inflammatory mediators
TNF-a and MMP9 were also determined by western blot.
Compared with controls, 6-OHDA produced significant increases
in the total amount of TNF- a and MMP9 (F[2,21]=284.56,
***p,0.001, 6-OHDA vs controls, n=6–9, Fig. 6); while these
increases were prevented by simvastatin treatment
(F[2,21]=284.56, {{{p,0.001, 6-OHDA vs 6-OHDA+sim,
n=6–9, Fig. 6).
Simvastatin attenuates the protein and size of NMDANR1
and TNF-a in 6-OHDA-treated PC12 cells
To further examine whether a simvastatin-induced decrease of
NMDANR1 receptors in the postsynaptic membrane may be
associated with levels of inflammatory cytokine TNF-a, 6-OHDA-
treated PC12 cells treated with simvastatin was subjected to
immunocytochemical staining. Numerous punctate clusters con-
taining NR1 immunoreactivity were found among synaptic cluster
(Fig. 7C). We compared the density and location of NMDANR1
receptor clusters in sets of randomly selected control, 6-OHDA-
treated, and 6-OHDA+simvastatin treated PC12 cells. As shown
in Fig. 7G, the quantification confirmed that the exposure of PC12
to 6-OHDA for 24 hrs greatly increased the density of NR1
clustering at the synaptic cleft (p,0.05, n=9–12, control vs 6-
OHDA), which is consistent with the results of western blot
analysis. However, incubation with simvastation significantly
abolished this up-regulation of NR1 clustering in the synaptic
arbors (p,0.05, 6-OHDA vs 6-OHDA+sim, n=9–12; Fig. 7K).
The simvastatin-mediated decrease of NR1 clusters to synaptic
sites suggests that NMDAR transport along the dendrite may be
altered or, alternatively, receptor protein stabilization may occur.
In addition, the quantification of TNF-a revealed a similar result:
TNF-a was present in the dendrites of PC12 cells and increased
after 24-hr 6-OHDA exposure (p,0.05, n=9–12, control vs 6-
OHDA; Fig. 7B and Fig. 7F). This elevation of TNF-a was
decreased following simvastatin treatment (p,0.05, 6-OHDA vs 6-
OHDA+sim, n=9–12; Fig. 7J). The similarities in the observed
similar patterns of NMDANR1 receptors and TNF-a expression in
the PC12 cultures suggest that the changes of NR1 receptors and
TNF-a are associated with simvastatin treatment.
Discussion
In this study, the pronounced reduction of TH immunore-
activity and decreased numbers of TH-immunoreactive dopa-
minergic neurons in the SNpc of the 6-OHDA-lesioned side
were observed, demonstrating an obvious dopaminergic neuro-
nal degeneration and complete nerve terminal denervation,
which are necessary for a successful PD animal model. Our
study also shows that simvastatin prevented 6-OHDA induced
dopaminergic neuronal loss, strongly implying that simvastatin
Figure 2. 2A. [
3H] MK-801 autoradiography depicts the expression of NMDA receptors in the rat brain. The maps of A, B and C are adopted from a
rat brain atlas indicating the levels where the [
3H]MK-801 binding density was measured. Autoradiographs (D, E, F) and (D’, E’, F’) depict the
expression of [
3H]MK-801 binding and non-specific [
3H]MK-801 binding at different rostro-caudal coronal levels of the rat brain. 2B. Typical
autoradiographs depict the expression of NMDA receptors in the hippocampus (Hipp) and amygdala (Amy) among control, 6-OHDA-lesioned rats,
and 6-OHDA lesioned rats that also received simvastatin treatment. The bar chart shows the effects of chronic simvastatin treatment on [
3H]MK-801
binding in the different groups of rat brain regions. Note: Units of measurement are in nCi/mg tissue. Data are means 6 SEM. Asterisks indicate
significant differences from control group (saline) and cross indicates significant differences between 6-OHDA rats and 6-OHDA with simvastatin-
treated rats (n=6–8, **p,0.01; ***p,0.001; {p,0.05; {{p,0.01; {{{p,0.001, one-way ANOVA followed by Tukey’s test).
doi:10.1371/journal.pone.0020945.g002
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consistent with Ghosh and Hernandez-Romero’s study, which
demonstrated that statins slowed down dopaminergic degener-
ation and may be of therapeutic benefit for PD patients [27,28].
It was shown that, in the EPM, 6-OHDA lesioned rats spent less
time in the open arm and an obvious decrease in the entries into
the open arm compared to the controls (Fig. 3A), reflecting
6-OHDA lesion-mediated anxiety-like behaviour. Our result is
consistent with Tadaiesky and Espejo’s studies demonstrating
that 6-OHDA lesioned PD rats showed increased anxiety-like
activityes [36,37]. Increasing evidence indicates that before the
motor features occur, Parkinson’s patients usually present one or
more nonmotor symptoms, typically as cognitive and neuropsy-
chiatric dysfunctions [38]. Among those neuropsychiatric
Figure 3. 3A. Simvastatin ameliorates the anxiety of 6-OHDA rats in the EPM test. The graph shows the ratio of time spent in the open arms to total
time and the ratio of open arm entries to total entries in the EPM. The parameters are expressed as a percentage of time spent in the open arms to
the total time and open arm entries to total entries in the EPM. The values represent mean 6 SEM, n=6–8. {p,0.05, 6-OHDA group versus 6-
OHDA+simvastatin group for open arm duration; ***p,0.001, 6-OHDA group versus control group for open arm duration; *p,0.05, 6-OHDA group
versus control group for open entires. 3B. Correlations between duration in the open arm of EPM and [
3H]MK-801 binding density in brain regions. A
significant positive correlation was identified between the [
3H]MK-801 binding density in the hippocampus (r=0.485 Pearson’s correlation, p=0.026),
amygdala (r=0.622, p=0.003), CA1 (r=0.638, p=0.002), respectively, and the time spent in the open arm of the EPM.
doi:10.1371/journal.pone.0020945.g003
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PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20945Figure 4. Simvastatin protected PC12 cells against 6-OHDA neurotoxicity. The MTT value in the 6-OHDA treated group was significantly
reduced as compared with controls (***p,0.001, 6-OHDA vs controls, n=9; Fig. 4A), but simvastatin upregulated this reduction ({{{p,0.001, 6-
OHDA vs 6-OHDA+sim, n=9; Fig. 4A). Intact nuclei (blue Hoechst 33342 staining) and condensed/fragmented nuclei (bright blue Hoechst 33342
staining) were considered to be live and apoptotic cells, respectively (Fig. 4B, C, D). The exposure of the PC12 cultures to 6-OHDA (100 uM, 24 h)
significantly increased the number of apoptotic cells by 4.75 times compared with controls (***p,0.001, 6-OHDA vs controls; Fig. 4E); however,
simvastatin incubation significantly reduced this increase in the number of apoptotic cells ({{{p,0.001, 6-OHDA vs 6-OHDA+sim; Fig. 4E;
Bar=100 mm). Apoptotic cells were further verified by flow cytometry analysis. The result showed that 6-OHDA induced profound apoptosis
(4.5960.9% vs 14.9761.25%, controls vs 6-OHDA, p,0.01, n=5; Fig. 4F and 6G) but simvastatin incubation attenuated this apoptotic death
(14.9761.25% vs 6.0960.64%, 6-OHDA vs 6-OHDA+sim, p,0.01, n=5; Fig. 4G and 4H). All the results are expressed as mean 6 standard error of the
mean.
doi:10.1371/journal.pone.0020945.g004
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prevalence rates of up to 30% depending on the criteria used
[39]. Therefore, it is imperative to explore the mechanisms
underlying the anxiety-like activity. The current animal study
directly reflects this neuropsychiatric profile in clinical PD
patients and suggests possible mechanisms.
Figure 5. Simvastatin reduced 6-OHDA-induced LDH and glutamate. LDH in 6-OHDA incubated PC12 increased by 1.74 times compared
with controls (***p,0.001, 6-OHDA vs controls, n=9; Fig. 5A), but simvastatin incubation abolished this elevation ({{{p,0.001, 6-OHDA vs 6-
OHDA+sim, n=9; Fig. 5A). In 6-OHDA incubated PC12, glutamate was increased by 1.43 times compared with controls (2.13860.03 mm vs
1.4960.01 mm, 6-OHDA vs controls, ***p,0.001, n=9; Fig. 5B), but simvastatin treatment abolished this elevation (2.13860.03 mm vs 1.6460.01 mm,
6-OHDA vs 6-OHDA+sim, {{{p,0.001, n=9; Fig. 5B). All of the results are expressed as mean 6 standard error of the mean.
doi:10.1371/journal.pone.0020945.g005
Figure 6. Simvastatin reduced 6-OHDA medicated elevations of NMDANR1 receptors, TNF-a, and MMP9. 6-OHDA incubation
pronouncedly increased the NR1 receptors compared with controls (***p,0.001, 6-OHDA vs controls, n=6–9); while this elevation was significantly
abolished following simvastatin treatment ({{{p,0.001, 6-OHDA vs 6-OHDA+sim, n=6–9). Compared with controls, 6-OHDA produced significant
increases in the total amount of TNF-a and MMP9 (***p,0.001, 6-OHDA vs controls, n=6–9); while these increases were prevented by simvastatin
treatment ({{{p,0.001, 6-OHDA vs 6-OHDA + sim, n=6–9). All the results are expressed as mean 6 standard error of the mean.
doi:10.1371/journal.pone.0020945.g006
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NMDA receptor expression in the brain regions examined
(Fig. 2B), which is similar to other studies, demonstrating that
NMDA receptors or its subunits were decreased in the brain
following unilateral dopamine depletion [40,41]. However, how
and why NMDA receptors were decreased following the 6-OHDA
MFB lesion remains to be conclusively determined. Several lines of
evidence demonstrated that striatal dopaminergic denervation
resulted in increased afferent glutamatergic input [42,43];
therefore, we hypothesize that the downregulation of NMDA
receptors in 6-OHDA lesioned rat brain is due to increased levels
of striatal glutamate following nigrostriatal dopamine denervation.
Notably, we cannot preclude that the downregulation of NMDA
receptors in the examined regions may reflect NMDA hypo-
innervations following 6-OHDA lesion. However, the precise
reasons behind this phenomenon remain to be determined.
It is well documented that NMDA receptors in the brain have a
close correlation with anxiety-like activity. In NMDA NR3B (N-
methyl,D-aspartate receptor subunit 3B) receptor knockout mice,
pronounced decrease in activity and increase in anxiety-like
behaviour were observed, suggesting that the function of the
NMDA receptor directly contributes to anxiety processing [44].
Similarly, Johnson and Shekhar found that anxiety-like responses
in rats were regulated by the NMDA NR1 subunit and NMDA
receptor antagonists [8]. Our current study showed that the
NMDA receptor was significantly decreased in the striatum,
hippocampus, CA1 and amygdala brain regions of the 6-OHDA
lesioned side. This robust downregulation of NMDA receptor in
the examined brain regions of 6-OHDA lesioned rats correlated
with longer duration of open-arm activity in the EPM (Fig. 3B),
strongly suggesting that the NMDA receptor hypofunction in these
brain regions explains, at least partially, the anxiety-like activity in
6-OHDA induced PD rats. This hypothesis could also be
supported by the facts that the altered levels of NMDA receptors
in the hippocampus and amygdala directly influence anxiety
behaviours [10,22].
In the current study, as our previous work and Byrnes’ study
[22,30], the elevated plus maze test was used to measure the
anxiety of rats following 6-OHDA lesion and simvatatin
treatment. Two indicators, the duration spent in the open arm
and entries into the open arm, were applied to evaluate the anxiety
of rats. Increased time, and/or entries traveled in the open arms of
the EPM are interpreted as reduced anxiety-like behavior. Our
data showed that when compared to 6-OHDA-lesion PD rats,
simvastatin only produced an increased tendency but not
significant effect in the entries into the open arms (p=0.060,
Fig. 3A). This result may be due to either the small numbers of rats
used in this study, or the rats being reluctant to move following the
6-OHDA lesion. This increased tendency in the entries into the
open arms following simvastatin treatment, at least partially,
Figure 7. 6-OHDA increased synaptic cluster density and number of clusters NR1 receptors and TNF-a, and the upregulation was
abolished after simvastatin treatment. Arrows in I, J, K indicate nuclear, TNF-a, and NR1, respectively. PC12 cultures double-labeled for NR1
(red, C,G,K) and TNF-a (green, B,F,J); Hoechst 33342 indicates nuclear staining (blue, A, E, I). 6-OHDA treatment significantly increased the density of
NR1 (G) and TNF-a clusters (F), and the elevated density was abolished by simvastatin treatment (K, J for NR1 and TNF-a, respectively). A significant
difference in the density of NR1 and TNF-a was observed among control, 6-OHDA, and 6-OHDA+sim groups (p,0.05, control vs 6-OHDA; p,0.05, 6-
OHDA vs 6-OHDA+sim; n=9–12; Student’s t test). All the results are expressed as means 6 standard error of the mean. Scale bars: 100 mm.
doi:10.1371/journal.pone.0020945.g007
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anxiety. Moreover, our results (Fig. 3A) also showed that
simvastatin administration profoundly increased the reduced time
spent by 6-OHDA lesioned rats in the open arm of the EPM
(Fig. 3A), reflecting the ability of simvastatin to produced a
pronounced anxiolytic-like effect. Consistent with our hypothesis,
in a retrospective cohort investigation Starr found that statins
obviously ameliorated anxiety disorder from in people aged 11–80
[45]. Increasing evidence shows that statins have been used
clinically to restore the cognitive deficits in different neurodegen-
erative disorders such as PD, AD and vascular dementia [46,47],
and the cumulative reduction in the levels of anxiety risk for
patients is independent of the statins’ cholesterol-lowering effect
[48]. However, how statins affect anxiety and the underlying
mechanisms remain unclear. This study showed that the down-
regulation of NMDA receptors in these examined regions was
obviously restored following simvastatin administration. The
present study is consistent with our previous observation in which
simvastatin upregulated NMDA receptors in the naı ¨ve rat brain,
and further validates our proposal that simvastain may exhibit
NMDA antagonist-like effects [22]. Our results demonstrated that
the upregulation of NMDA receptors in the hippocampus, CA1
and amygdala following simvastatin treatment had a significant
positive correlation with the time spent in the open arm of the
EPM (Fig. 3B), implying that simvastatin ameliorated anxiety
behaviour in 6-OHDA lesioned rats via NMDA receptor
modulation. Because previous studies have found that simvastatin
affected dopamine levels as well as its metabolism in vivo [20], and
because there exists a close interaction between the regulation of
NMDA receptors and the dopaminergic system [49,50], it is
reasonable to speculate that simvastatin may exhibit an anxiolytic-
like activity in 6-OHDA-lesioned rats by modulating the
expression of NMDA receptors in the examined brain regions or
influencing the interaction of NMDA receptors and the central
dopaminergic system.
To explore the effects of simvastatin on PD in an in vitro model,
6-OHDA treated PC12 cells, an accepted PD in vitro model, were
used in this study. The 6-OHDA incubated PC12 cultures
exhibited an obvious decrease of cell viability and increased
apoptosis (Fig. 4), indicating the establishment of a successful in
vitro PD model. However, pre-incubation with simvastatin
reduced cell viability and increased apoptosis, as determined
using Hoechst 33342 and flow cytometry analysis. In addition, our
results showed that LDH and glutamate were significantly
increased in 6-OHDA-induced PC12 cells. These elevations were
obviously prevented after simvastatin incubation, demonstrating
that simvastatin induced pronounced neuroprotective effects.
PC12 cells mainly express the functional NR1 receptor; therefore
NR1 was chosen to detect the effects of 6-OHDA neurotoxicity
and simvastatin in this study. It has been shown that the elevation
of NMDA receptors is closely correlated with inflammatory
responses and induced neuronal death [51,52,53]. In the current
study, the increased NR1 expression and excitatory glutamate
concentration were observed following 6-OHDA incubation
(Figs. 5 and Fig. 6). This 6-OHDA induced elevation of glutamate
excessively activated NMDANR1 expression, which further
aggravated PC12 damage [54] and may have increased the
susceptibilityof PC12 cells to excitotoxicity. However, the addition
of simvastatin significantly abolished this elevation of NR1 and
glutamate as well as the reduction in PC12 cell death. Considering
that the elevation of NR1 and glutamate will lead to excitotoxicity
and neuronal cell death, it is reasonable to speculate that in the
current study simvastatin prevented PC12 cell death, at least
partially, by protecting against NR1-induced excitotoxicity. This
result is similar to Wang’s study, showing that the upregulation of
NR1 was correlated with neuronal cell death and abolishing this
NR1 elevation prevented neuronal loss [55]. Interestingly, we
observed that the changes of NMDA receptors following 6-OHDA
and simvastatin treatment in vivo and in vitro PD models are
contrary. These contrasting results may be that in vivo PD model
the animals responded with auto-regulation to dopaminergic
damage; while in vitro PD model only PC12 cells react to micro-
environment changes following 6-OHDA and simvastatin treat-
ment. However, the precise mechanisms need further study.
To explore whether inflammatory mediators in PC12 cells
changed following 6-OHDA and simvastatin treatment, we
measured the expression of TNF-a and MMP9. Our study
showed increased expression of TNF-a and MMP9 in 6-OHDA-
induced PC12 cells (Fig. 6), implying that these inflammatory
mediators affected NMDA receptors expression. The elevation
of NR1 and TNF-a and MMP9 was significantly abolished
following simvastatin treatment, strongly suggesting a direct
anti-inflammatory property of simvastatin through NMDA
receptor modulation. The current result is consistent with
several lines of evidence showing that the regulation of NMDA
receptors is directly correlated with inflammatory mediators
TNF-a and MMPs in pathological brain processes, including the
mediation of neuronal death [56,57,58]. To further verify that
the alteration of NMDA receptors is associated with inflamma-
tory cytokine TNF-a, we focused specifically on 6-OHDA-
t r e a t e dP C 1 2e x p r e s s i n gN R 1p r o t e i na n da n a l y z e dt h ep a t t e r n
and distribution of the punctate extranuclear immunostaining of
TNF-a proteins presenting along dendrites. We detected a
significant increase in NR1 protein clusters after 6-OHDA
exposure; this increase was abolished following simvastatin
treatment, whereas TNF-a proteins displayed a similar pattern
after 6-OHDA neurotoxicity and simvastatin treatment (Fig. 7).
The changed trend of TNF-a and NR1 proteins in our study
(Fig. 7) indicated that NR1 proteins were closely associated with
inflammatory cytokine TNF-a following 6-OHDA and simvas-
tatin treatment. This result is consistent with other studies
showing that pro-inflammatory mediator TNF-a is involved in
simvastatin-mediated neuroprotection and associated with the
altered expression of NMDA receptors [59]. To the best of our
knowledge, this is the first attempt to describe the TNF-a and
NR1 in PC12 and their similar changes in expression following
inflammation.
In summary, our study presents the first evidence demonstrat-
ing the effects of simvastatin on NMDA receptors in the brain of
6-OHDA-lesioned rats and reveals an NMDA-modulatory effect,
providing an exciting new paradigm to ameliorate anxiety-like
activity in PD. Based on the current results, we reasonably
speculate that the improvement in anxiety-like activity due to
chronic treatment with simvastatin in 6-OHDA-lesioned rats is
partially correlated with a reversal of the declined in NMDA
receptors expression. Through in vitro and in vivo studies, our
results strongly demonstrated that simvastatin provided robust
neuroprotection against dopaminergic neurodegeneration, par-
tially via NMDA receptor mediated anti-inflammatory mecha-
nisms such as regulating TNF-a and MMP9. Although it is not a
complete phenocopy of human disease, this 6-OHDA-mediated
in vivo or in vitro PD models provides a useful means to study the
pathomechanisms of clinical PD patients, as the models
recapitulates many of the hallmarks of PD. A better understand-
ing of the roles and relationships among statins, NMDA, and the
dopaminergic system may open new perspectives for the statin
family in the modulation of psycho-neurodegenerative disorders
such as PD.
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